Sumitomo Pharma (Myovant)

Sumitomo Pharma, based in Osaka, is the Japanese pharmaceutical company that makes Orgovyx, or relugolix, the first oral GnRH antagonist for prostate cancer, after acquiring Myovant Sciences in 2023. In the HERO trial relugolix gave rapid and reversible testosterone suppression without the flare seen with GnRH agonists, and with fewer major cardiovascular events in that trial. OnCo links it to prostate cancer and to the relugolix drug record. Whether an oral daily tablet improves adherence and outcomes over long-acting injections in routine practice, rather than in a trial, is the open question. Relugolix has its own page with the approval detail.